A clinician’s guide to ADHD treatment options

References

• Thapar A, Cooper M, Eyre O, et al. Practitioner review: what have we learnt about the causes of ADHD? J of Child Psychol and Psychiatry. 2013;54(1):3–16.
   PubMed Web of Science ®Google Scholar
• Visser SN, Zablotsky B, Holbrook JR, et al. Diagnostic experiences of children with attention-deficit/Hyperactivity disorder. Natl Health Stat Report. 2015;(81):1–7. Available from https://www.ncbi.nlm.nih.gov/pubmed/26375578
   PubMedGoogle Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723.
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–409.
   PubMed Web of Science ®Google Scholar
• Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34–46 e2.
   PubMed Web of Science ®Google Scholar
• Ustun B, Adler LA, Rudin C, et al. The World Health Organization adult attention-deficit/Hyperactivity disorder self-report screening scale for DSM-5. JAMA Psychiatry. 2017;74(5):520–526.
   PubMed Web of Science ®Google Scholar
• Caye A, Rocha TB, Anselmi L, et al. Attention-deficit/Hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry. 2016;73(7):705–712.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–165.
   PubMed Web of Science ®Google Scholar
• Cortese S, Faraone SV, Bernardi S, et al. Gender differences in adult attention-deficit/hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2016;77(4):e421–e428.
   PubMed Web of Science ®Google Scholar
• Almeida Montes LG, Hernandez Garcia AO, Ricardo-Garcell J. ADHD prevalence in adult outpatients with nonpsychotic psychiatric illnesses. J Atten Disord. 2007;11(2):150–156.
   PubMedGoogle Scholar
• Biederman J, Kwon A, Aleardi M, et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry. 2005;162(6):1083–1089.
   PubMed Web of Science ®Google Scholar
• Yoshimasu K, Barbaresi WJ, Colligan RC, et al. Adults with persistent ADHD: gender and psychiatric comorbidities-a population-based longitudinal study. J Atten Disord. 2016.
   PubMed Web of Science ®Google Scholar
• Kooij JJ, Huss M, Asherson P, et al. Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord. 2012;16(5Suppl):3S–19S.
   PubMed Web of Science ®Google Scholar
• Epstein JN, Loren RE. Changes in the definition of ADHD in DSM-5: subtle but Important. Neuropsychiatry (London). 2013;3(5):455–458.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
   Google Scholar
• American Psychiatric Association. Highlights of changes from DSM-IV-TR to DSM-5, in diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013. p. 809–818.
   Google Scholar
• Culpepper L, Mattingly G. Challenges in identifying and managing attention-deficit/hyperactivity disorder in adults in the primary care setting: a review of the literature. Prim Care Companion J Clin Psychiatry. 2010;12(6):e1–e7.
   Google Scholar
• Mattingly G, Surman CB, Mao AR, et al. Improving communication in ADHD Care: results from In-office linguistic research. CNS Spectr. 2011;16(4):85–94.
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Leckman JF, Mortensen PB, et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015;2(8):702–709.
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Ostergaard SD, Leckman JF, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190–2196.
   PubMed Web of Science ®Google Scholar
• London AS, Landes SD. Attention deficit hyperactivity disorder and adult mortality. Prev Med. 2016;90:8–10.
   PubMed Web of Science ®Google Scholar
• Chien WC, Chung CH, Lin FH, et al. The risk of injury in adults with attention-deficit hyperactivity disorder: a nationwide, matched-cohort, population-based study in Taiwan. Res Dev Disabil. 2017;65:57–73.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Goldenberg M, Perry R, et al. The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci. 2012;9(5–6):10–21.
   PubMedGoogle Scholar
• Peasgood T, Bhardwaj A, Biggs K, et al. The impact of ADHD on the health and well-being of ADHD children and their siblings. Eur Child Adolesc Psychiatry. 2016;25(11):1217–1231.
   PubMed Web of Science ®Google Scholar
• Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114(5):e541–7.
   PubMed Web of Science ®Google Scholar
• Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry. 2002;41(5):530–537.
   PubMed Web of Science ®Google Scholar
• Charach A, Yeung E, Climans T, et al. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50(1):9–21.
   PubMed Web of Science ®Google Scholar
• Curry AE, Metzger KB, Pfeiffer MR, et al. Motor vehicle crash risk among adolescents and young adults with attention-deficit/Hyperactivity disorder. JAMA Pediatr. 2017. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Blase SL, Gilbert AN, Anastopoulos AD, et al. Self-reported ADHD and adjustment in college: cross-sectional and longitudinal findings. J Atten Disord. 2009;13(3):297–309.
   PubMed Web of Science ®Google Scholar
• Brook JS, Brook DW, Zhang C, et al. Adolescent ADHD and adult physical and mental health, work performance, and financial stress. Pediatrics. 2013;131(1):5–13.
   PubMed Web of Science ®Google Scholar
• Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1):97–107.
   PubMed Web of Science ®Google Scholar
• Rabito-Alcon MF, Correas-Lauffer J. Treatment guidelines for attention deficit and hyperactivity disorder: a critical review. Actas Esp Psiquiatr. 2014;42(6):315–324.
   PubMed Web of Science ®Google Scholar
• Berek M, Kordon A, Hargarter L, et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS(R) MPH: is treatment response different between children and adolescents? Child Adolesc Psychiatry Ment Health. 2011;5:26.
   PubMedGoogle Scholar
• Blader JC, Pliszka SR, Kafantaris V, et al. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1281–1293.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–2014.
   PubMed Web of Science ®Google Scholar
• Chang Z, Quinn PD, Hur K, et al. Association between medication use for attention-deficit/Hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017;74(6):597–603.
   PubMed Web of Science ®Google Scholar
• Bihlar Muld B, Jokinen J, Bolte S, et al. Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study. J Subst Abuse Treat. 2015;51:82–90.
   PubMed Web of Science ®Google Scholar
• Chen MH, Pan TL, Hsu JW, et al. Attention-deficit hyperactivity disorder comorbidity and antidepressant resistance among patients with major depression: a nationwide longitudinal study. Eur Neuropsychopharmacol. 2016;26(11):1760–1767.
   PubMed Web of Science ®Google Scholar
• Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/Hyperactivity disorder in youths. P T. 2009;34(12):678–694.
   PubMedGoogle Scholar
• Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–763.
   PubMed Web of Science ®Google Scholar
• Coghill D, Hodgkins P. Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. Eur Child Adolesc Psychiatry. 2016;25(3):261–271.
   PubMed Web of Science ®Google Scholar
• Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000;3(4):200–211.
   Google Scholar
• Lopez FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013;5(3):249–265.
   PubMedGoogle Scholar
• Dyanavel XR (amphetamine) extended-release oral suspension  [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; 2015. Available from http://www.dyanavelxr.com/pdfs/pi.pdf
   Google Scholar
• Procentra (dextroamphetamine sulfate) oral solution [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; 2015. Available from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1548cce2-fb6b-4f17-8a3b-868933f6c9d6
   Google Scholar
• Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets  [package insert]. Grand Prairie, TX: Neos Therapeutics LP.; 2015. Available from http://www.neostxcontent.com/Labeling/Adzenys/Adzenys_PI.pdf
   Google Scholar
• Adderall XR (mixed salts of a single-entity amphetamine product) dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulfate capsules  [package insert]. Wayne, PA: Shire US Inc.; 2015. Available from http://pi.shirecontent.com/PI/PDFs/AdderallXR_USA_ENG.PDF
   Google Scholar
• Dexedrine (dextroamphetamine sulfate) SPANSULE® sustained-release capsules and tablets  [package insert]. Horsham, PA: Amedra Pharmaceuticals LLC; 2015. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a37b6ef9-78b4-4b18-8797-ecb583502500
   Google Scholar
• Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for oral use  [package insert]. Wayne, PA: Shire US Inc.; 2017. Available from http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf
   Google Scholar
• Mydayis (mixed salts of a single-entity amphetamine product) extended-release capsules for oral use [package insert]. Lexington, MA: Shire US Inc.; 2017. Available from http://www.shirecontent.com/PI/PDFs/Mydayis_USA_Eng.pdf
   Google Scholar
• Evekeo (amphetamine sulfate tablets, USP) [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; 2016. Available from https://www.evekeo.com/pdfs/evekeo-pi.pdf?v=1496932091614
   Google Scholar
• Zenzedi (dextroamphetamine sulfate, USP)  [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; 2017. Available from http://zenzedi.com/docs/PIandMedicationGuide.pdf
   Google Scholar
• Desoxyn (methamphetamine hydrochloride tablets, USP)  [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc.; 2013. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/005378s028lbl.pdf
   Google Scholar
• Adderall (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets) [package insert]. Horsham, PA: Teva Select Brands; 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/011522s043lbl.pdf
   Google Scholar
• Metadate CD (methylphenidate HCl, USP) extended-release capsules  [package insert]. Smyrna, GA: UCB, Inc.; 2014. Available from http://www.ucb.com/_up/ucb_com_products/documents/Metadate_CD_COL_02_2015.pdf
   Google Scholar
• Metadate ER (methylphenidate hydrochloride extended-release tablets, USP)  [package insert]. Smyrna, GA: Upstate Pharma, LLC; 2014. Available from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=739bbd64-d9e1-4771-967b-a2cd08f4eaf5
   Google Scholar
• Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension  [package insert]. New York, NY: NextWave Pharmaceuticals, Inc. a subsidiary of Pfizer Inc.; 2015.
   Google Scholar
• Quillichew ER (methylphenidate hydrochloride) extended-release chewable tablets for oral use  [package insert]. New York, NY: NextWave Pharmaceuticals, Inc.; 2015. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf
   Google Scholar
• Ritalin LA (methylphenidate hydrochloride) extended-release capsules  [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015. Available from https://www.pharma.us.novartis.com/product/pi/pdf/ritalin_la.pdf
   Google Scholar
• Aptensio XR (methylphenidate hydrochloride extended-release) capsules for oral use  [package insert]. Coventry, RI: Rhodes Pharmaceuticals L.P.; 2015. Available from http://aptensioxr.com/resources/full-prescribing-information.pdf
   Google Scholar
• Daytrana (methylphenidate transdermal system)  [package insert]. Miami, FL: Noven Pharmaceuticals, Inc.; 2015. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f
   Google Scholar
• Concerta (methylphenidate HCl) Extended-Release Tablets  [package insert]. Titusville, NJ.: Janssen Pharmaceuticals Inc.; 2015. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd
   Google Scholar
• Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules for oral use  [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015. Available from https://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf
   Google Scholar
• Methylphenidate Hydrochloride extended-release tablets USP, for oral use  [package insert]. Hazelwood, MO: Mallinckrodt Inc.; 2015. Available from http://www2.mallinckrodt.com/Templates/Pages/productdetail.aspx?id=2147483767
   Google Scholar
• Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets)  [package insert]. Grand Prairie, TX: Neos Therapeutics, Inc.; 2017. Available from http://www.neostxcontent.com/Labeling/Cotempla/Cotempla_PI.pdf
   Google Scholar
• Ritalin hydrochloride methylphenidate hydrochloride USP tablets & Ritalin-SR methylphenidate hydrochloride USP sustained-release tablets  [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018029s055lbl.pdf
   Google Scholar
• Methylin Oral Solution (methylphenidate HCl oral solution)  [package insert]. Florham Park, NJ: Shionogi Inc.; 2013. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021419s014lbl.pdf
   Google Scholar
• Methylin Chewable Tablets (methylphenidate HCl chewable tablets)  [package insert]. Florham Park, NJ: Shionogi Inc.; 2013. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09f13452-8f90-426e-9687-d30be75db9d7
   Google Scholar
• Focalin dexmethylphenidate hydrochloride tablets  [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021278s023lbl.pdf
   Google Scholar
• Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31.
   PubMed Web of Science ®Google Scholar
• Jain R, Stark JG. Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications. Postgrad Med. 2016;128(7):672–681.
   PubMed Web of Science ®Google Scholar
• Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs. 2009;23(Suppl 1):21–31.
   PubMed Web of Science ®Google Scholar
• Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 2014;134(4):e935–e944.
   PubMed Web of Science ®Google Scholar
• Strattera (atomoxetine hydrochloride) Capsules for Oral Use  [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017. Available from http://pi.lilly.com/us/strattera-pi.pdf
   Google Scholar
• Intuniv (guanfacine) extended-release tablets for oral use  [package insert]. Lexington, MA: Shire US, Inc.; 2016. Available from http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf
   Google Scholar
• Kapvay (clonidine hydrochloride) extended-release tablets oral  [package insert]. Bridgetown, Barbados: Concordia Pharmaceuticals Inc.; 2016. Available from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7700e2-ae5d-44c4-a609-76de19c705a7
   Google Scholar
• Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121–129.
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Shaw M, Coghill D, et al. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477–492.
   PubMed Web of Science ®Google Scholar
• Rostain A, Jensen PS, Connor DF, et al. Toward quality care in ADHD: defining the goals of treatment. J Atten Disord. 2015;19(2):99–117.
   PubMed Web of Science ®Google Scholar
• Mattingly GW, Anderson RH. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS Spectr. 2016;21(S1):45–59.
   PubMed Web of Science ®Google Scholar
• Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2009;14(10):573–585.
   PubMed Web of Science ®Google Scholar
• Mattingly G, Childress A, Nordbrock E, et al. Clinical response and symptomatic remission with Aptensio XR (methylphenidate extended realease) in children and adolescents with ADHD. Poster session presented at: American Psychiatry Association Meeting; 2016 May 14–18; Atlanta, GA.
   Google Scholar
• Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569.
   PubMed Web of Science ®Google Scholar
• McCarthy S. Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence? Patient Prefer Adherence. 2014;8:1317–1327.
   PubMed Web of Science ®Google Scholar
• Brinkman WB, Sherman SN, Zmitrovich AR, et al. Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics. 2009;124(2):580–589.
   PubMed Web of Science ®Google Scholar
• Childress A Patients’ with ADHD and healthcare professionals’ perspectives on available ADHD formulations, swallowing tablets and capsules, and treatment adherence. Poster session presented at: The American Professional Society of ADHD and Related Disorders Annual Meeting; 2016 Jan 15–17; Washington, DC.
   Google Scholar
• Harris Interactive Inc. Pill-swallowing problems in America: a National Survey of Adults. New York, NY: Harris Interactive Inc., for Schwarz Pharma; 2003. p. 1–39.
   Google Scholar
• Adler LA, Lynch LR, Shaw DM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med. 2011;123(5):71–79.
   PubMed Web of Science ®Google Scholar
• Palli SR, Kamble PS, Chen H, et al. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(2):139–148.
   PubMed Web of Science ®Google Scholar
• Gau SS, Chen SJ, Chou WJ, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry. 2008;69(1):131–140.
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008;22(7):603–611.
   PubMed Web of Science ®Google Scholar
• Neos therapeutics submits NDA for amphetamine extended-release liquid suspension drug candidate, NT-0201, for the Treatment of ADHD [press release]. Dallas/Fort Worth, Texas: Neos Therapeutics, Inc.; 2016 Nov 17. cited 2017 Apr 4. Available from: http://investors.neostx.com/phoenix.zhtml?c=254075&p=RssLanding&cat=news&id=2223314
   Google Scholar
• Noven announces positive phase 2 results of investigational d-amphetamine transdermal system for ADHD [press release]. Noven Pharmaceuticals, Inc.; 2013 July 29. [cited 2017 Apr 5]. Available from: http://www.firstwordpharma.com/node/1126945#axzz4dO0cgSiu
   Google Scholar
• Ironshore Pharmaceuticals announces FDA acceptance of HLD200 new drug application for treatment of ADHD [press release]. George Town, Grand Cayman: Highland Therapeutics Inc.; 2016 Dec 15. cited 2017 Apr 4. Available from: http://www.highlandtherapeutics.com/pdf/Ironshore-Pharmaceuticals-Announces-FDA-Acceptance-HLD200-NDA-.pdf
   Google Scholar
• Stark JG, Engelking D, McMahen R, et al. Pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in children with attention-deficit/Hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(3):216–222.
   PubMed Web of Science ®Google Scholar
• San L, Casillas M, Ciudad A, et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther. 2008;14(3):203–214.
   PubMed Web of Science ®Google Scholar
• Stark JG, Engelking D, McMahen R, et al. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. Postgrad Med. 2016;128(7):648–655.
   PubMed Web of Science ®Google Scholar
• Childress AC, Kollins SH, Cutler AJ, et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/Hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66–74.
   PubMed Web of Science ®Google Scholar
• Findling RL, Dinh S. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). CNS Drugs. 2014;28(3):217–228.
   PubMed Web of Science ®Google Scholar
• Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26(10):920–935.
   PubMed Web of Science ®Google Scholar